Piramal Enterprises, incorporated in the year 1947, is a large cap company with a market cap of Rs 42,468.87 Crore, operating in diversified sector.
Piramal Enterprises key products/revenue segments include pharmaceuticals, interest, dividend, sale of services, income from financial services and other operating revenue for the year ending 31-Mar-2020.
Investment rationale
The brokerage has increased the target price for the company due to robust base in each of its segment – CDMO (58 per cent of sales), Complex Hospital Generics (CHG; 34 per cent of sales), and India Consumer Products (ICP; 8 per cent of sales), with this Piramal Enterprises has built multiple levers to drive growth over the next 4-5 years
Financials
For the quarter ended 31-12-2020, the company has reported a Consolidated Total Income of Rs 3,264.82 Crore, down 2.23 per cent from last quarter’s Total Income of Rs 3,339.39 Crore and down 17.28 per cent from last year same quarter’s Total Income of Rs 3,947 Crore. Company has reported net profit after tax of Rs 651.99 Crore in latest quarter.
Promoter/FII Holdings
Promoters held 46.1 per cent stake in the company as of Dec 30, 2020, while FIIs held 29.3 per cent, DIIs 10.5 per cent and public and others 14.1 per cent.
